ANSWER: C

Rationale:

Tumor lysis syndrome results from the massive and rapid release of intracellular contents when large numbers of tumor cells die simultaneously after cytotoxic therapy begins. The biology that maximizes this risk is the combination of a large tumor cell mass (a large absolute number of cells to lyse), a high proliferative rate (a high growth fraction that makes the tumor exquisitely chemosensitive), and high intrinsic chemosensitivity (so that treatment kills a large fraction quickly). Burkitt lymphoma with bulky disease and a markedly elevated white cell count and lactate dehydrogenase is the prototypical highest-risk setting because all three features coincide. Recognizing this triad is what prompts pre-emptive tumor lysis prophylaxis before the first dose of chemotherapy.

• Option A: Option A describes the lowest-risk profile, the opposite of this patient.
• Option B: Option B is incorrect because a low proliferative rate and low chemosensitivity would produce slow, limited cell death and low tumor lysis risk despite a large mass.
• Option D: Option D is incorrect because low chemosensitivity limits the rapid simultaneous cell death that drives the syndrome, and a small mass provides few cells to lyse.
• Option E: Option E is incorrect because tumor lysis risk is fundamentally determined by tumor biology — mass, proliferation, and chemosensitivity — not by age alone.

ANSWER: A

Rationale:

The metabolic abnormalities of tumor lysis syndrome follow directly from the rapid release of intracellular contents as tumor cells die. Intracellular potassium release produces hyperkalemia; intracellular phosphate release produces hyperphosphatemia; catabolism of released nucleic acids produces hyperuricemia; and the elevated phosphate binds calcium and precipitates, producing a secondary hypocalcemia. The dangerous consequences flow from these derangements: hyperkalemia can cause fatal arrhythmias, uric acid can crystallize in renal tubules and cause acute kidney injury, and hypocalcemia can cause tetany or seizures. Anticipating this quartet is what allows the team to monitor for and treat the syndrome before it becomes life-threatening.

• Option B: Option B incorrectly reverses the true pattern and is wrong on every value.
• Option C: Option C is incorrect because sodium and glucose are not the defining disturbances and uric acid is elevated, not low.
• Option D: Option D is incorrect because potassium and phosphate are elevated and calcium is low in tumor lysis syndrome, the opposite of what is listed.
• Option E: Option E is incorrect because calcium is low and phosphate is high in tumor lysis syndrome, even though it correctly notes the elevated uric acid.

ANSWER: D

Rationale:

The two agents act at different points on the uric acid pathway. Allopurinol is a xanthine oxidase inhibitor that blocks the formation of new uric acid but does nothing to the uric acid already present. Rasburicase is recombinant urate oxidase that enzymatically degrades existing uric acid to allantoin, a highly soluble product that is readily excreted, and therefore rapidly lowers an elevated burden — the preferred action for a patient who already has a high uric acid level. The critical safety consideration is that rasburicase is absolutely contraindicated in G6PD deficiency, because the reaction generates hydrogen peroxide that G6PD-deficient red cells cannot detoxify, producing severe hemolysis. Integrating mechanism with safety is what governs the choice of agent in this high-risk patient.

• Option A: Option A is incorrect because only rasburicase degrades existing uric acid, and rasburicase carries the absolute G6PD contraindication.
• Option B: Option B reverses the two mechanisms.
• Option C: Option C is incorrect because rasburicase is urate oxidase, not a xanthine oxidase inhibitor, and it does lower the pre-existing burden.
• Option E: Option E is incorrect because rasburicase is not a xanthine oxidase inhibitor and is specifically unsafe in G6PD deficiency.

ANSWER: B

Rationale:

Because the patient is confirmed G6PD deficient, rasburicase is absolutely contraindicated: the hydrogen peroxide generated by the rasburicase reaction would cause severe, potentially life-threatening hemolysis in his G6PD-deficient erythrocytes. With chemotherapy unable to wait, the safe and effective strategy is aggressive intravenous hydration combined with allopurinol. Hydration maximizes urinary uric acid excretion and dilutes crystallizing anions, while allopurinol inhibits xanthine oxidase to block formation of additional uric acid. This combination provides robust prophylaxis without exposing the patient to the hemolytic danger of rasburicase, integrating the safety contraindication with the practical urgency of his presentation.

• Option A: Option A is incorrect and dangerous because dose reduction does not make rasburicase safe in G6PD deficiency; the contraindication is absolute.
• Option C: Option C is incorrect because withholding prophylaxis in a patient at very high tumor lysis risk is unsafe.
• Option D: Option D is incorrect because giving rasburicase to a G6PD-deficient patient and attempting to offset hemolysis with transfusion is not an acceptable strategy; the drug must be avoided.
• Option E: Option E is incorrect because aggressive hydration is a cornerstone of tumor lysis prophylaxis and should not be omitted when allopurinol is used.

ANSWER: E

Rationale:

Methotrexate is a hydrophilic, water-soluble drug, and a large third-space collection such as a pleural effusion behaves as a reservoir into which the drug distributes. After the plasma concentration falls, the sequestered drug is slowly released back into the systemic circulation, prolonging exposure well beyond the expected duration and increasing the risk of mucositis and myelosuppression without a proportional gain in antitumor effect. For this reason, large effusions should be drained before high-dose methotrexate, so the third-space reservoir cannot convert a controlled exposure into a dangerously prolonged one. This is the canonical example of how a distribution compartment, rather than a clearance defect, can drive unexpected toxicity.

• Option A: Option A is incorrect because the effusion does not accelerate metabolism; it acts as a slow-release reservoir that prolongs exposure.
• Option B: Option B is incorrect because methotrexate is not irreversibly bound and inactivated; it redistributes back into the circulation in active form.
• Option C: Option C is incorrect because the mechanism is third-space sequestration and slow release, not mechanical ureteral obstruction.
• Option D: Option D overstates the effect; the issue is delayed redistribution producing prolonged exposure, not the absence of any measurable plasma concentration.

ANSWER: C

Rationale:

Methotrexate is cleared predominantly by the kidney through both glomerular filtration and active tubular secretion. NSAIDs such as ibuprofen interfere with that renal tubular secretion, slowing methotrexate elimination and prolonging systemic exposure. In this patient the hazard is compounding: the pleural effusion already provides a slow-release reservoir that prolongs exposure, and the NSAID independently impairs clearance of the drug in the circulation, so the two effects stack to push total exposure toward dangerous levels. The appropriate action is therefore to withhold the ibuprofen before high-dose methotrexate, in addition to draining the effusion, so that both contributors to prolonged exposure are removed.

• Option A: Option A reverses the interaction: NSAIDs delay clearance and raise exposure rather than accelerating elimination, so increasing the dose would be dangerous.
• Option B: Option B is incorrect because NSAIDs do interact significantly with methotrexate by reducing tubular secretion.
• Option D: Option D is incorrect because the interaction is pharmacokinetic, occurring at the renal tubule, not a pharmacodynamic displacement at the target enzyme.
• Option E: Option E is incorrect because NSAIDs do not inactivate methotrexate via hepatic metabolism; the harm comes from prolonged exposure to active drug, which requires holding the NSAID.

ANSWER: A

Rationale:

Methotrexate acts by inhibiting dihydrofolate reductase, the enzyme that regenerates the reduced folates required for purine and thymidine synthesis. When the tumor amplifies the DHFR gene and manufactures far more enzyme than normal, the achievable methotrexate concentration can no longer inhibit all of it; the residual uninhibited fraction is sufficient to keep regenerating reduced folates and sustain DNA synthesis. This is the prototypic example of resistance by target amplification — overwhelming the drug with an excess of its target — and it is distinct from efflux-pump and drug-inactivation mechanisms. Recognizing the mechanism explains why simply escalating the methotrexate dose may be insufficient once substantial amplification has occurred.

• Option B: Option B describes drug efflux, the mechanism of P-glycoprotein, not the function of dihydrofolate reductase, which is a metabolic enzyme that does not transport drugs.
• Option C: Option C is incorrect because dihydrofolate reductase does not chemically degrade methotrexate; resistance arises from sheer excess of the target enzyme.
• Option D: Option D is incorrect because gene amplification operates inside the tumor cell and does not affect intestinal absorption.
• Option E: Option E is incorrect because dihydrofolate reductase does not activate methotrexate; methotrexate is administered in active form and inhibits the enzyme directly.

ANSWER: B

Rationale:

Methotrexate is an S-phase-specific antimetabolite. By inhibiting dihydrofolate reductase it depletes the reduced folates required to synthesize purine and thymidine nucleotides, so it is lethal only to cells that are actively synthesizing DNA during the exposure period. Two consequences follow: its dose-response curve plateaus, because once the cells currently in S phase are killed, additional drug has no further target until new cells enter S phase; and extending the duration of exposure, rather than escalating a single dose beyond the plateau, is what increases total cell kill. This links the drug's classification to its scheduling behavior, which is why methotrexate regimens emphasize adequate exposure duration.

• Option A: Option A is incorrect because spindle disruption in M phase is the mechanism of the vinca alkaloids and taxanes, not methotrexate.
• Option C: Option C is incorrect because methotrexate is cycle-specific and does not kill quiescent G0 cells, which are not synthesizing DNA.
• Option D: Option D is incorrect because methotrexate acts in S phase by depleting nucleotide precursors, not in G2 by blocking mitotic entry.
• Option E: Option E is incorrect because methotrexate activity is tightly linked to the cell cycle and to active proliferation, which is the basis of its S-phase specificity.

ANSWER: D

Rationale:

The rationale requires combining two principles. The log-kill hypothesis holds that each cycle kills a constant fraction of cells, so the number of cycles needed for cure scales with the starting cell number; at the very low burden of microscopic residual disease, a defined number of cycles can drive the population below one viable cell. Gompertzian kinetics adds that small deposits sit in the high-growth-fraction, near-exponential region of the curve and are therefore more chemosensitive than the bulky primary tumor was. Microscopic adjuvant disease enjoys both advantages — low cell number and high growth fraction — which is precisely why adjuvant chemotherapy can eradicate disease that cannot be seen on imaging, even though the same regimen might not cure bulky recurrent disease.

• Option A: Option A is incorrect because adjuvant therapy targets undetectable microscopic disease, not visible residual tumor; the premise is that imaging shows no disease.
• Option B: Option B is incorrect because microscopic disease is precisely what adjuvant therapy can eradicate, and the benefit is well established, not merely conventional.
• Option C: Option C inverts the kinetics: small deposits, not bulky ones, have the higher growth fraction and greater chemosensitivity.
• Option E: Option E incorrectly contradicts the Gompertzian model, in which the growth fraction falls as tumor size rises, making timing relative to burden highly relevant.

ANSWER: B

Rationale:

In responsive, potentially curable disease such as node-positive breast cancer treated with adjuvant intent, the delivered dose intensity is a determinant of outcome, and retrospective analyses have linked falling below planned intensity to worse disease-free and overall survival. The limiting toxicity in this scenario is hematologic, which is exactly the toxicity that granulocyte colony-stimulating factor support can mitigate by accelerating neutrophil recovery. Integrating these facts, the preferred path when feasible is to preserve dose intensity using growth-factor support rather than reflexively reducing the dose, because an arbitrary reduction may forfeit curative potential to manage a toxicity that has a specific supportive remedy. The decision should weigh the goal of cure against the manageable nature of the neutropenia.

• Option A: Option A is incorrect because dose reduction is not automatically correct in curative-intent therapy; preserving intensity with supportive care is often preferable.
• Option C: Option C incorrectly contradicts the established relationship between dose intensity and outcome in responsive tumors.
• Option D: Option D is incorrect because growth factor given after chemotherapy does accelerate neutrophil recovery, which is the basis for using it to preserve dose intensity.
• Option E: Option E is incorrect because cure depends on dose intensity, not solely on the number of cycles; reducing dose per cycle lowers intensity.

ANSWER: E

Rationale:

Dose density is the strategy of shortening the interval between cycles while holding the per-cycle dose constant. Its rationale derives from the Norton-Simon hypothesis: after each cycle, the surviving residual disease is small and therefore sits in the high-growth-fraction, near-exponential region of the Gompertz curve, where it regrows rapidly during the recovery interval. Compressing that interval shortens the window available for regrowth, so the next cycle strikes before the residual disease has rebounded, raising effective dose intensity without increasing the per-cycle dose. This is why dose-dense scheduling improved outcomes in node-positive breast cancer, and why it requires growth-factor support to remain deliverable.

• Option A: Option A describes high-dose therapy with stem cell rescue, a distinct strategy based on per-cycle dose escalation, not interval compression.
• Option B: Option B inverts dose density, which shortens rather than lengthens the interval.
• Option C: Option C is incorrect because dose density maintains the per-cycle dose rather than reducing it.
• Option D: Option D is incorrect because dose density refers to the timing of cycles, not to infusion-bag concentration.

ANSWER: A

Rationale:

Two points combine here. The timing rule exists because granulocyte colony-stimulating factor stimulates neutrophil precursors to proliferate, and proliferating cells are precisely those most vulnerable to cycle-specific cytotoxic agents; starting it while chemotherapy drug levels remain high could deepen myelosuppression, so it is begun roughly 24 to 72 hours after chemotherapy. The pharmacokinetic advantage is that pegfilgrastim, formed by conjugating filgrastim to a 20-kilodalton polyethylene glycol molecule, has markedly reduced renal clearance — the primary elimination route of filgrastim — which prolongs its half-life to approximately 33 hours and permits a single per-cycle injection instead of the daily injections required with filgrastim. In a dose-dense regimen, single per-cycle dosing is particularly convenient and reliable.

• Option B: Option B is incorrect on both counts: growth factor is not given simultaneously with chemotherapy, and PEGylation reduces rather than increases renal clearance, lengthening the dosing interval.
• Option C: Option C is incorrect because growth factor is given after, not before, chemotherapy, and pegfilgrastim is dosed far less frequently than filgrastim.
• Option D: Option D is incorrect because timing is important and pegfilgrastim is a subcutaneous injection, not an oral agent.
• Option E: Option E is incorrect because growth-factor support is essential to dose-dense therapy and pegfilgrastim differs substantially from filgrastim in pharmacokinetics.

ANSWER: C

Rationale:

Choosing agents with non-overlapping dose-limiting toxicities allows each drug to be given at or near its full single-agent dose, because their worst toxicities fall on different organs rather than stacking on one. This preserves the dose intensity that drives efficacy while combining several independent mechanisms of action, and it underlies the design of curative regimens. In a regimen built on this principle, one agent might dose-limit on myelosuppression, another on neuropathy, and another contribute activity with minimal marrow toxicity, so the combination achieves a far greater effect than any single agent could at tolerable doses. The principle is about distributing toxicity across organs to permit full dosing, not about minimizing the dose.

• Option A: Option A inverts the principle, which seeks non-overlapping rather than shared dose-limiting organs.
• Option B: Option B is incorrect because the aim is to maintain full effective doses of each agent, not to shrink the total dose.
• Option D: Option D overstates the result; combination chemotherapy still produces substantial toxicity, just distributed across organs.
• Option E: Option E is incorrect because cost reduction is not the rationale; preserving dose intensity and combining mechanisms are the design goals.

ANSWER: A

Rationale:

The mathematical foundation of combination chemotherapy is that, when resistance to each agent arises independently, the probability that a single tumor cell is simultaneously resistant to all of them is the product of the individual probabilities. If resistance to each of two drugs occurs at roughly one in a million, the chance of a cell resisting both at once is about one in a trillion — below the number of cells present even in microscopic disease. Using agents with non-cross-resistant mechanisms therefore makes it statistically very unlikely that any single resistant subclone can survive the entire regimen, which is why curative regimens combine mechanistically distinct drugs. The strategy depends on the independence of the resistance events, which non-overlapping mechanisms help to ensure.

• Option B: Option B overstates the principle; combination dramatically reduces but does not absolutely guarantee elimination of a multiply resistant cell.
• Option C: Option C inverts the logic: combining non-cross-resistant drugs lowers, not raises, the probability that a cell resists the whole regimen.
• Option D: Option D is incorrect because the probability of surviving treatment is far lower with multiple independent agents than with one.
• Option E: Option E is incorrect because resistance suppression depends on combining distinct, independent mechanisms, not on total dose alone.

ANSWER: D

Rationale:

The MOPP-to-ABVD transition is a model of therapeutic-index improvement. The change was driven not by a gain in cure rate but by a reduction in serious long-term harm at preserved efficacy: the alkylating-agent components of MOPP carried substantial risks of secondary leukemia and infertility, and ABVD achieved equivalent or superior cure rates with markedly lower rates of these late toxicities. Integrating efficacy with long-term toxicity into the single concept of therapeutic index shows that a curative regimen can be refined by swapping components to lower the toxicity burden at equal benefit. This matters especially in a young patient with potentially curable Hodgkin lymphoma who may live for decades and experience late effects.

• Option A: Option A is incorrect because regimen replacement is justified by improving the therapeutic index, including reducing long-term toxicity at equal efficacy, not only by raising cure rates.
• Option B: Option B is incorrect because long-term toxicities are highly relevant in curable disease, where cured patients survive to experience them.
• Option C: Option C incorrectly overgeneralizes; reducing drug number does not by itself guarantee improved efficacy and safety, and ABVD's advantage came from changing which agents were used.
• Option E: Option E misattributes the transition to cost rather than the toxicity-versus-efficacy balance.

ANSWER: B

Rationale:

Bleomycin's defining cumulative toxicity is pulmonary: it produces dose-related lung injury that can progress to pulmonary fibrosis, which is why a strict cumulative dose limit is observed. A clinically important related precaution is that patients who have received bleomycin are vulnerable to oxygen-potentiated lung injury, so supplemental high-concentration oxygen is avoided in the perioperative period whenever feasible. In a regimen such as the one used for germ cell tumors and in bleomycin-containing Hodgkin regimens, this pulmonary risk shapes both the cumulative dosing and perioperative oxygen management. Recognizing the lung as the target organ is essential to using bleomycin safely.

• Option A: Option A is incorrect because nephrotoxicity is characteristic of cisplatin, not the principal cumulative toxicity of bleomycin.
• Option C: Option C is incorrect because cumulative cardiomyopathy is the hallmark of the anthracyclines, not bleomycin.
• Option D: Option D is incorrect because dose-limiting peripheral neuropathy characterizes the vinca alkaloids, not bleomycin.
• Option E: Option E is incorrect because bleomycin has a major cumulative pulmonary toxicity that requires a cumulative dose limit and specific oxygen precautions.

ANSWER: E

Rationale:

Cisplatin is characteristically nephrotoxic, and cumulative exposure across cycles can produce a measurable decline in glomerular filtration rate. This direct renal injury matters beyond the kidney itself: a falling GFR changes the pharmacokinetics of renally cleared agents and may necessitate dose adjustment or substitution — for example, switching to carboplatin dosed by the Calvert formula — in subsequent cycles. Recognizing cisplatin nephrotoxicity as the driver of the declining renal function is the first step in adjusting the ongoing platinum strategy for this patient, and it explains why renal function is monitored closely during cisplatin therapy.

• Option A: Option A is incorrect because cisplatin is well known to be nephrotoxic, so the renal decline is plausibly drug-related.
• Option B: Option B is incorrect because cisplatin does not improve renal blood flow; it injures the kidney.
• Option C: Option C is incorrect because cisplatin is not hepatically eliminated in a way that spares the kidney; it is directly nephrotoxic.
• Option D: Option D is incorrect because the mechanism is direct renal injury, not hypertension-mediated reduction in filtration without renal damage.

ANSWER: C

Rationale:

Carboplatin is eliminated almost entirely by glomerular filtration, so its clearance tracks GFR. The Calvert formula sets the dose to achieve a target AUC as a function of GFR, which is exactly what this patient with reduced renal function requires: a body-surface-area dose, which ignores kidney function, would deliver a relative overdose because her impaired kidneys clear the drug more slowly, risking severe myelosuppression. Targeting exposure directly through the Calvert formula calibrates the dose to her actual clearance and delivers the intended AUC safely. This is the canonical example of pharmacokinetically guided dosing, and impaired renal function is the circumstance in which it most clearly outperforms body-surface-area dosing.

• Option A: Option A is incorrect because body surface area does not capture renal function, so the methods diverge substantially in renal impairment.
• Option B: Option B is incorrect because carboplatin is renally, not hepatically, cleared.
• Option D: Option D is incorrect because the Calvert formula is specifically valid and preferred when renal function has changed.
• Option E: Option E is incorrect because AUC-based dosing concerns dose calculation, not route; carboplatin is given intravenously.

ANSWER: B

Rationale:

Lipid solubility is a primary determinant of how a drug distributes. Hydrophilic agents such as carboplatin and methotrexate have small volumes of distribution that approximate the extracellular fluid volume; they remain closer to the bloodstream and, for carboplatin, are cleared predictably by renal filtration. Lipophilic agents such as the nitrosoureas and anthracyclines have large volumes of distribution, partitioning extensively into tissues, and lipophilicity is one of the structural features that favors penetration of sanctuary sites such as the central nervous system. Understanding this contrast explains both the predictable renal handling of carboplatin and why certain lipophilic agents are chosen when central nervous system penetration is needed.

• Option A: Option A is incorrect because hydrophilic agents have small, not large, volumes of distribution and do not sequester in adipose tissue.
• Option C: Option C is incorrect because lipid solubility strongly influences tissue distribution and volume of distribution.
• Option D: Option D is incorrect because lipophilic agents are not confined to the bloodstream; their lipophilicity actually favors crossing the blood-brain barrier.
• Option E: Option E inverts the relationship: lipophilicity, not water solubility, favors penetration of the blood-brain barrier.

ANSWER: A

Rationale:

Platinum compounds such as cisplatin and carboplatin are cycle-nonspecific agents: they form platinum-DNA adducts that damage DNA regardless of where the cell is in the division cycle, so they kill both cycling and quiescent G0 cells. Because their lethality is not gated by phase availability, their dose-response relationship is more nearly linear over a wider dose range than that of phase-specific agents, where increasing dose continues to increase cell kill rather than reaching an early plateau. This is why platinum agents retain activity against tumors with lower growth fractions and why dose is a more direct determinant of their effect, in contrast to the schedule-dependence of phase-specific drugs.

• Option B: Option B is incorrect because platinum compounds are cycle-nonspecific, not S-phase specific, and do not show the early plateau characteristic of phase-specific agents.
• Option C: Option C is incorrect because spindle disruption in M phase is the mechanism of the vinca alkaloids and taxanes, not the platinum compounds.
• Option D: Option D is incorrect because platinum agents kill G0 cells rather than sparing them, and the prolonged-infusion rationale applies to phase-specific drugs.
• Option E: Option E is incorrect because platinum compounds act precisely by damaging DNA through adduct formation, not by inhibiting microtubules.

ANSWER: D

Rationale:

Anthracycline extravasation is a genuine oncologic emergency because doxorubicin binds tissue DNA and is released slowly from necrotic tissue, producing injury that continues to advance for weeks. The correct response is to stop the infusion immediately, aspirate residual drug through the existing catheter, and administer dexrazoxane intravenously within six hours — the only FDA-approved antidote for anthracycline extravasation. The six-hour window is not flexible, and cooling is avoided in this setting because it reduces local blood flow and therefore dexrazoxane delivery to the tissue. Prompt recognition and early dexrazoxane administration are what limit progression to deep necrosis.

• Option A: Option A is incorrect because warm compresses plus hyaluronidase is the vinca alkaloid protocol, and the infusion must be stopped, never continued.
• Option B: Option B is incorrect and dangerous because doxorubicin is a vesicant, not an irritant, and untreated extravasation causes progressive necrosis.
• Option C: Option C describes the antidote for mechlorethamine extravasation, not anthracyclines.
• Option E: Option E is incorrect because the infusion must be stopped and not resumed, and cooling is avoided when dexrazoxane is used.

ANSWER: B

Rationale:

The distinction governs how extravasation is managed. A vesicant causes severe tissue destruction, blistering, and potentially deep necrosis that may require surgical debridement or skin grafting if it leaks into surrounding tissue; the anthracyclines, vinca alkaloids, mechlorethamine, and mitomycin C are important vesicants. An irritant causes pain, inflammation, and phlebitis at and proximal to the injection site but does not produce tissue necrosis; agents such as carboplatin, cisplatin, and etoposide at standard concentrations are irritants. Doxorubicin is a vesicant, which is why its extravasation is an emergency. The distinction is not absolute — concentrated solutions of nominally irritant drugs can behave as vesicants — but the categories drive the urgency and type of intervention.

• Option A: Option A reverses the definitions.
• Option C: Option C is incorrect because vesicants and irritants differ fundamentally in their tissue effects, not merely in route.
• Option D: Option D is incorrect because vesicant status is a property of the drug's tissue toxicity, not of the venous access used.
• Option E: Option E inverts the relationship: vesicants, not irritants, cause the more severe tissue injury.

ANSWER: E

Rationale:

Febrile neutropenia is defined as fever with an absolute neutrophil count well below 500 cells per microliter, and this patient with a temperature of 38.7 degrees Celsius and a count of 300 cells per microliter clearly qualifies. Her hypotension marks her as high risk, which mandates hospital admission and prompt empiric intravenous anti-pseudomonal beta-lactam therapy, most commonly piperacillin-tazobactam, administered within one hour, because gram-negative organisms including Pseudomonas can cause rapid, fatal deterioration in the neutropenic host. Empiric therapy must begin before culture results are available; delay risks irreversible decompensation. This integrates recognition of the diagnostic threshold with the correct risk-stratified management.

• Option A: Option A is incorrect because the definition requires a count below 500 cells per microliter, which she meets at 300, so urgent antibiotics are required.
• Option B: Option B is incorrect because her hypotension makes her high risk, for which oral outpatient management is unsafe.
• Option C: Option C is incorrect because she is neutropenic, not merely febrile.
• Option D: Option D is incorrect because she has fever, and empiric therapy must not be deferred pending cultures.

ANSWER: A

Rationale:

Simultaneous resistance to three structurally unrelated drugs from different classes is the defining signature of classic multidrug resistance, and its most extensively characterized cause is overexpression of P-glycoprotein. This ATP-dependent efflux pump has a broad substrate range that includes the anthracyclines (doxorubicin), the vinca alkaloids (vincristine), and the taxanes (paclitaxel), among others. By actively pumping all of these hydrophobic compounds out of the cell, a single overexpressed transporter lowers the intracellular concentration of each below cytotoxic thresholds at the same time, producing cross-resistance across agents that share no common structure or mechanism. Recognizing this pattern guides the choice of salvage agents that are not P-glycoprotein substrates.

• Option B: Option B is incorrect because dihydrofolate reductase amplification confers resistance specifically to methotrexate, not to anthracyclines, vinca alkaloids, and taxanes.
• Option C: Option C is incorrect because dihydropyrimidine dehydrogenase deficiency relates to 5-fluorouracil, not these three drugs.
• Option D: Option D is incorrect because loss of the copper influx transporter CTR1 reduces uptake of platinum agents, not the drugs in this case.
• Option E: Option E is incorrect because thymidylate synthase is the target of fluoropyrimidines; doxorubicin, vincristine, and paclitaxel act on topoisomerase II and the microtubule apparatus, so a single thymidylate synthase mutation cannot explain resistance to all three.